newsfilter
← Latest News
Business Wire·

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating